Delivery Order SPE2DB22D1017-SPE2DB23FF5YK
- Not listed
- This federal contract award, valued at $8,295.59, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialty pharmaceutical product, to DLA facilities supporting the Department of Defense's (DoD) healthcare programs. The contract is a Delivery Order placed under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at...
- This federal contract award, valued at $48,403.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Stelara 90 mg/ml syringes, a specialty medication. This is a firm fixed-price delivery order contract with a period of performance ending on January 31, 2024. The contract was awarded on an unrestricted, full and open competition basis with no set-aside designation. Amerisourcebergen Drug Corp is a...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an award value of $8,101.84 and covers the delivery of the pharmaceutical product STELARA 45 MG/0.5 ML SYRINGE 0.5ML. The contract is a Firm Fixed Price Delivery Order with a completion date of May 10, 2024. Amerisourcebergen Drug Corp has an existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $9,366.01 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes and has a completion date of June 21, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of...
- This federal contract award is held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract, awarded by the Defense Logistics Agency (DLA), is a Delivery Order valued at $21,288.35 for the pharmaceutical product STELARA 90 MG/ML SYRINGE. This contract has an ultimate completion date of April 10, 2023 and is a Firm Fixed Price arrangement. The award was made without any set-aside designation, indicating open competition....
- This federal contract award, valued at $34,467.56, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Stelara 90 mg/ml syringes, a specialty pharmaceutical product. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an award value of $25,038.52 and is for the delivery of STELARA 90 MG/ML SYRINGEML. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 4, 2024. This contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- This federal contract award, valued at $82,480.90, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a completion date of November 23, 2021. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $6,715.70 for the supply of STELARA 90 MG/ML SYRINGEML. The award was made by the Defense Logistics Agency (DLA) and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as...
- This federal contract award, valued at $16,915.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract covers the delivery of Stelara 90 mg/ml syringes, a specialty pharmaceutical product, with a completion date of February 13, 2024. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a major pharmaceutical distributor and...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB23FF5YKDelivery Order
This federal contract award, valued at $7,001.46, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with an ultimate completion date of April 24, 2023. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it was awarded on April 21, 2023. The contract is not designated with any set-aside requirements, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. Additionally, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 4/21/23 |